Item 2.02 Results of Operations and Financial Condition.
Please see the disclosure relating to the estimated cash and investments in
marketable securities of Nektar Therapeutics, a Delaware corporation (the
"Company"), set forth under Item 7.01 "Regulation FD Disclosure" of this Current
Report on Form 8-K, which is incorporated by reference into this Item 2.02.
Item 7.01 Regulation FD Disclosure.
On January 5, 2022, the Company announced that President and Chief Executive
Officer, Howard Robin, will make a presentation at the upcoming 40th Annual J.P.
Morgan Virtual Healthcare Conference on Tuesday, January 11, 2022, at 3:00 p.m.
Eastern Time. The presentation and Q&A session will be accessible via a Webcast
through a link posted on the Investor Events Calendar section of the Company's
website: https://ir.nektar.com/events-and-presentations/events. This Webcast
will be available for replay until February 11, 2022.
In addition, Mr. Robin intends to announce that, based upon the Company's
preliminary estimates, as of December 31, 2021, the Company had cash and
investments of approximately $800 million. This financial information has been
prepared by and is the responsibility of the Company's management and has not
been audited by the Company's independent registered public accounting firm.
Accordingly, the Company's independent registered public accounting firm does
not express an opinion on or provide any other form of assurance with respect to
this preliminary data. This financial information is subject to the completion
of the Company's year-end financial closing procedures, the preparation of the
Company's consolidated financial statements, and the completion of the audit of
the Company's consolidated financial statements as of and for the year ended
December 31, 2021, and the Company's actual results may differ from these
estimates.
The Company expects the presentation and Q&A session will include certain
forward-looking statements regarding the Company's business and proprietary drug
candidates, the therapeutic and commercial potential of the Company's drug
candidates, the timing of the start and conclusion of planned or ongoing
clinical trials, the timing and outcome of regulatory decisions, and the timing
and future availability of clinical trial data. Actual results could differ
materially from these forward-looking statements, which are subject to important
risks and uncertainties set forth in the Company's Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission on November 5, 2021. The
Company undertakes no obligation to update forward-looking statements, whether
as a result of new information, future events or otherwise.
The information in this report is being furnished and shall not be deemed
"filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, or otherwise subject to the liabilities of that Section or Sections 11
and 12(a)(2) of the Securities Act of 1933, as amended. The information
contained in this report shall not be incorporated by reference into any other
filing with the Securities and Exchange Commission made by the Company, whether
made before or after the date hereof, regardless of any general incorporation
language in such filing.
1
© Edgar Online, source Glimpses